Abstract
The Italian Co-operative Group GIMEMA conducted a randomized trial in adult acute nonlymphocytic leukemia (ANLL) to assess the role of postconsolidation treatment. Of 448 evaluable patients entered into the study, 305 (68%) achieved a complete remission after a standard induction with daunorubicin and cytosine arabinoside (3+7; 2+5). Those in remission after a consolidation therapy including 4 courses of daunorubicin, cytosine arabinoside, and 6-thioguanine (DAT) were allocated to one of three arms: no treatment, conventional maintenance, or intensive postconsolidation therapy. The median disease-free survival (DFS) was 13 months, and the median survival was 14 months, with 26% surviving at 6.5 years. There was no difference in survival and in disease-free survival among the three postconsolidation arms. In conclusion our study, as others, suggests that the critical period of ANLL treatment is within the first 5-6 months.
| Original language | English |
|---|---|
| Pages (from-to) | 166-172 |
| Number of pages | 7 |
| Journal | Annals of Hematology |
| Volume | 64 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 1992 |
Fingerprint
Keywords
- Adult acute nonlymphocytic leukemia
- Chemotherapy
- Post-consolidation approaches
ASJC Scopus subject areas
- Hematology
Cite this
A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia : a report of the Italian Cooperative Group GIMEMA. / Mandelli, E.; Vegna, M. L.; Awisati, G.; Amadori, S.; Spadea, A.; Cacciola, E.; Cantore, N.; De Laurenzi, A.; De Rosa, C.; Fioritoni, G.; Gabbas, A.; Liso, V.; Malleo, C.; Miraglia, E.; Montillo, M.; Perricone, R.; Peta, A.; Ricduti, F.; Petti, M. C.
In: Annals of Hematology, Vol. 64, No. 4, 04.1992, p. 166-172.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia
T2 - a report of the Italian Cooperative Group GIMEMA
AU - Mandelli, E.
AU - Vegna, M. L.
AU - Awisati, G.
AU - Amadori, S.
AU - Spadea, A.
AU - Cacciola, E.
AU - Cantore, N.
AU - De Laurenzi, A.
AU - De Rosa, C.
AU - Fioritoni, G.
AU - Gabbas, A.
AU - Liso, V.
AU - Malleo, C.
AU - Miraglia, E.
AU - Montillo, M.
AU - Perricone, R.
AU - Peta, A.
AU - Ricduti, F.
AU - Petti, M. C.
PY - 1992/4
Y1 - 1992/4
N2 - The Italian Co-operative Group GIMEMA conducted a randomized trial in adult acute nonlymphocytic leukemia (ANLL) to assess the role of postconsolidation treatment. Of 448 evaluable patients entered into the study, 305 (68%) achieved a complete remission after a standard induction with daunorubicin and cytosine arabinoside (3+7; 2+5). Those in remission after a consolidation therapy including 4 courses of daunorubicin, cytosine arabinoside, and 6-thioguanine (DAT) were allocated to one of three arms: no treatment, conventional maintenance, or intensive postconsolidation therapy. The median disease-free survival (DFS) was 13 months, and the median survival was 14 months, with 26% surviving at 6.5 years. There was no difference in survival and in disease-free survival among the three postconsolidation arms. In conclusion our study, as others, suggests that the critical period of ANLL treatment is within the first 5-6 months.
AB - The Italian Co-operative Group GIMEMA conducted a randomized trial in adult acute nonlymphocytic leukemia (ANLL) to assess the role of postconsolidation treatment. Of 448 evaluable patients entered into the study, 305 (68%) achieved a complete remission after a standard induction with daunorubicin and cytosine arabinoside (3+7; 2+5). Those in remission after a consolidation therapy including 4 courses of daunorubicin, cytosine arabinoside, and 6-thioguanine (DAT) were allocated to one of three arms: no treatment, conventional maintenance, or intensive postconsolidation therapy. The median disease-free survival (DFS) was 13 months, and the median survival was 14 months, with 26% surviving at 6.5 years. There was no difference in survival and in disease-free survival among the three postconsolidation arms. In conclusion our study, as others, suggests that the critical period of ANLL treatment is within the first 5-6 months.
KW - Adult acute nonlymphocytic leukemia
KW - Chemotherapy
KW - Post-consolidation approaches
UR - http://www.scopus.com/inward/record.url?scp=0026593794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026593794&partnerID=8YFLogxK
U2 - 10.1007/BF01696218
DO - 10.1007/BF01696218
M3 - Article
C2 - 1581404
AN - SCOPUS:0026593794
VL - 64
SP - 166
EP - 172
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 4
ER -